The FDA has granted Breakthrough Therapy designation for litifilimab for the treatment of cutaneous lupus erythematosus, a chronic autoimmune skin disease.

Litifilimab, a humanized immunoglobulin G1 monoclonal antibody that targets blood dendritic cell antigen 2, has been granted ...

Both subacute cutaneous lupus and discoid lupus are a form of lupus skin disease, though they have some distinct differences. Subacute cutaneous lupus may show up as ring-shaped red, scaly lesions.

And then acute cutaneous lupus, which includes having a butterfly rash that comes out often with sun exposure, and can look like either pink or red on the malar areas of the cheeks. And very often ...

The striking benefits achieved with emerging treatment options for recalcitrant connective tissue diseases offer the ...

Please provide your email address to receive an email when new articles are posted on . Victoria P. Werth, MD, professor of dermatology at the University of Pennsylvania Hospital, and chief of ...

The Lupus Research Alliance applauds the decision by the U.S. Food and Drug Administration (FDA) to grant Breakthrough Therapy designation for litifilimab (BIIB059) in clinical development by Biogen ...

Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed ...

Increased odds of atherosclerotic cardiovascular disease seen in association with cutaneous lupus and systemic lupus, but not psoriasis. HealthDay News — Cutaneous lupus erythematosus (CLE) is ...

This autoimmune disease may impact your skin as well as your nails and hair. Learn what to look for to treat lupus more effectively.

Feb 3 (Reuters) - AstraZeneca said on Tuesday that the U.S. health regulator had rejected its application for an ...

The FDA has granted breakthrough therapy designation for litifilimab in patients with cutaneous lupus erythematosus, ...